VivoSeq
Other

Delayed Graft Function

0

Pipeline Programs↗

2

Active Trials↗

4

Companies Involved↗

Delayed Graft Function is an early-stage landscape with 0 programs across 4 companies. The most active players are Y's Therapeutics, Inc., GSK, Apellis Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Y

Y's Therapeutics, Inc.

0 programs

PreclinicalGSK logo

GSK

0 programs

PreclinicalApellis Pharmaceuticals logo

Apellis Pharmaceuticals

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed6 · 50%
Terminated2 · 17%
Unknown status2 · 17%
Recruiting1 · 8%
Active, not recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
Recruiting·Apellis Pharmaceuticals logoApellis Pharmaceuticals·Phase 3·NCT07020832·320 enrolled
Calcineurin Inhibitor in NEuRoloGically Deceased Donors to Decrease Kidney delaYed Graft Function (CINERGY)
Active, not recruiting·UUniversité de Sherbrooke·Phase 2·NCT05148715·414 enrolled
YSPSL for Prevention of Delayed Graft Function Part A
Completed·YY's Therapeutics, Inc.·N/A·NCT00298181·15 enrolled
Envarsus in Delayed Graft Function (E-DGF)
Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT03864926·100 enrolled
YSPSL for Prevention of Delayed Graft Function Part B
Completed·YY's Therapeutics, Inc.·Phase 1/2·NCT00298168·60 enrolled
Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation
Completed·WWest Penn Allegheny Health System·Phase 4·NCT00425126·76 enrolled
Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation
Completed·MMedical University of Vienna·Phase 3·NCT02705573·34 enrolled
Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)
Completed·AstraZeneca logoAstraZeneca·Phase 2/3·NCT02145182·288 enrolled
Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation
Terminated·GSK logoGSK·Phase 2·NCT02723786·7 enrolled
Tacrolimus to Sirolimus Conversion for Delayed Graft Function
Terminated·UUniversity of Maryland, Baltimore·Phase 4·NCT00931255·32 enrolled
RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function
Unknown status·UUniversity of Wisconsin, Madison·Phase 1·NCT03791476·20 enrolled
Study on Delayed Graft Function Using Paired Kidneys
Unknown status·AAngion Biomedica Corp·Phase 2·NCT01561599·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)